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Long-term careAbstract Objectives: Inappropriate antimicrobial use can promote antimicrobial
resistance, which is associated with increased patient morbidity and mortality.
Identifying the pattern of antimicrobial use can provide data from which targeted
antimicrobial stewardship interventions can be made. The primary objective was
to identify the prevalence of antimicrobial use at a tertiary care teaching hospital
with both acute and long-term care patients.
Methods: A point prevalence study was conducted on July 19th, 2012. Data on anti-
microbial utilization, indication for prescribing, duration of therapy, and frequency of
infectious disease or antimicrobial stewardship consultations were collected using a
customized integrated stewardship database (SPIRIT) and prospective chart review.
Results: One ormore antimicrobial agents were ordered in 31% and 4% of acute care
and long-term care patients, respectively. Respiratory and urinary tract infections
were the most common indication for antimicrobial therapy in both acute and long-
term care. About 25% of surgical prophylaxis orders were prescribed for greater than
24 h.
Conclusion: This prospective point prevalence survey provided important baseline
information on antimicrobial use within a large tertiary care teaching hospital and
identified potential targets for future antimicrobial stewardship initiatives.
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antimicrobial use in Canada and to establish the first steps toward international
antimicrobial surveillance.
ª 2014 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Antimicrobial resistance is an unavoidable conse-
quence of antimicrobial use and is correlated with
the overall use of these agents [1,2]. It has been
reported that approximately one third of patients
admitted to hospital receive an antimicrobial agent
during their hospital stay [3–5]. This is particularly
problematic when up to 50% of all courses of antimi-
crobial therapy are deemed unnecessary [4,6,7].
Antimicrobial resistance is increasing and is a con-
cern because it is associated with increased patient
length of hospital stay, mortality, and cost. [8,9]
Since both frequent and prolonged use of anti-
microbial agents may promote the emergence of
resistance [10,11], antimicrobial stewardship is rec-
ommended as a means of reducing antimicrobial
resistance, along with lowering the risk of adverse
drug events, treatment complications, and institu-
tional costs [7,12]. It is important for institutions
to understand their patterns of antimicrobial use
to identify appropriate stewardship interventions
that have the greatest likelihood of impacting insti-
tutional antimicrobial utilization and therefore, the
aforementioned consequences of antimicrobial use.
We conducted a point prevalence survey to
quantify antimicrobial utilization and determine
patterns of use at a Canadian tertiary care teaching
hospital and affiliated long-term care facility. It is
hoped that this information will serve as a baseline
for future point-prevalence surveys, and provide a
measure of the effect of antimicrobial stewardship
interventions. The primary objective of this survey
was to determine the prevalence of patients in the
hospital and residing in the associated long-term
care facility who were receiving at least one antimi-
crobial agent, and the prevalence of individual anti-
microbial orders on the survey date. The secondary
objective of this study was to describe the pattern
of antimicrobial prescribing (choice of antimicrobial
agent, indication, and duration of therapy).
2. Methods
The point prevalence survey was conducted at
Sunnybrook Health Sciences Centre, a 1212-bed
adult teaching hospital in Toronto, Ontario,Canada, with acute care facilities and an adjoining
veterans long-term complex care facility. The hos-
pitals programs include aging, trauma, oncology,
neurosciences, women and babies, cardiac and
musculoskeletal diseases. There is a multi-disci-
plinary antimicrobial stewardship program (ASP),
which prospectively audits the use of targeted anti-
microbials and consults with prescribers on days 3,
7, and 14 of therapy [13,14]. Targeted antimicrobi-
als include fluoroquinolones, third generation
cephalosporins, carbapenems, aminoglycosides,
vancomycin, and piperacillin-tazobactam. At the
time of the survey, ASP services were being
provided to most acute-care inpatient units but
not to the long-term care units.
The survey was conducted on July 19, 2012, and
included inpatients who were receiving a systemic
antibacterial, antifungal, or antiviral agent on that
day. Neonates, emergency room patients who were
not yet admitted, palliative care patients, and
obstetric patients were excluded from the survey.
Orders for anti-retroviral, anti-tuberculous, and
anti-parasitic medications were also excluded from
the survey.
Patients were identified through the Steward-
ship Program Integrated Resource Information
Technology (SPIRIT) database, which receives
inputs in real time from the hospitals pharmacy,
microbiology, hematology and biochemistry labo-
ratories and the admission/discharge and transfer
databases [14]. The data elements of interest were
abstracted directly from the SPIRIT database and
supplemented by prospective review of electronic
and paper charts by an infectious diseases physi-
cian or pharmacist with the aid of a standardized
electronic form.
Prevalence in this study was determined using
the number of patients receiving at least one anti-
microbial agent or a number of antimicrobial
orders as the numerator, and the total number
of inpatients (excluding patients previously
described) as the denominator standardized to
1000 patients on the study day. Antimicrobials in
this survey were presented as classes defined by
the Anatomical Therapeutic Chemical (ATC) classi-
fication system from the World Health Organization
(WHO) Collaborating Centre for Drug Statistics
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as being definitive, empiric, prophylactic, or
unknown. Definitive treatment was defined as
treatment that was started when either a site of
infection or a pathogenic microorganism causing
infection was identified. Empiric treatment was
defined as treatment that was started for a pre-
sumed or possible infection without a site or
infecting organism being identified. Prophylaxis
was defined as the use of an antimicrobial agent
in order to prevent an infection when an infection
was not already present. Treatment indication was
categorized as unknown if there was no identifiable
reason for antimicrobial use after review of the
medical records. The duration of therapy was pre-
sented as the number the days from the date of
antimicrobial initiation to the date of survey.
3. Results
A total of 1021 eligible patients were identified on
the survey date; 508 in acute care and 513 in long-
term care. Since our long-term care facility is the
largest veterans care facility in Canada, there
was a male predominance in our long-term care
resident population (53% in acute care and 86% in
long term care) (Table 1).
A total of 174 per 1000 patients were receiving
at least one antimicrobial agent on the day of the
study (Table 2); a prevalence of 308 per 1000 acute
care patients, and 41 per 1000 long-term care res-
idents. The majority of patients (65%) receiving
antimicrobial therapy received only one antimicro-
bial agent (Table 2). There were a total of 244 anti-
microbial orders per 1000 patients; a prevalence of
449 per 1000 acute care patients, and 41 per 1000
long-term care residents. The prevalence of
patients on at least one antibiotic agent was 298
per 1000 acute care patients, and 39 per 1000
long-term care residents.Table 1 Demographics of patients who received anti-
microbial treatment.
Description Acute care
(n = 508)
Long-term care
(n = 513)
Age* (years) 68 90
58–81 89–92
Male (%) 82 (53) 18 (86)
Length of stay* (days) 7 245
3–18 35–986
* Median and interquartile range (first quarter and third
quarter) since data not normally distributed.In the acute setting, the majority of antimicro-
bial orders were for antibiotics (207/228; 91%), fol-
lowed by antifungals (16/228; 7%), and antivirals
(5/228; 2%). In the long-term care setting, the
majority of antimicrobial orders were for antibiot-
ics (20/21; 95%), followed by antivirals (1/21; 5%)
(Fig. 1).
Fluoroquinolones, cephalosporins, and penicil-
lins were the most common classes of antibiotics
ordered, accounting for more than half of all anti-
biotic use within the entire institution (143/227;
63%). Fluconazole was the most common antifungal
prescribed, making up 50% (8/16) of all antifungal
orders while oseltamivir was the most common
antiviral prescribed, making up 67% (4/6) of all
antiviral orders within the entire institution.
Anti-pseudomonal antibiotics (aminoglycosides,
carbapenems, ceftazidime, ciprofloxacin, and
piperacillin–tazobactam) accounted for 30% (62/
207) of antibiotics in acute care, and 10% (2/20)
of antibiotics in long-term care. Ciprofloxacin
accounted for 44% (27/62) of all anti-pseudomonal
antibiotics used in acute care.
In the acute care setting, 38% (86/228) of all
antimicrobials were ordered as an oral agent, while
in long-term care, 86% (18/21) of antimicrobials
were ordered as an oral agent. The use of oral
formulation for antibiotics with high oral bioavail-
ability in the acute care setting was 68% (25/37)
for fluoroquinolones, 20% (1/5) for clindamycin,
27% (6/22) for metronidazole, and 67% (6/9) for
co-trimoxazole. Antimicrobials were ordered most
frequently for definitive treatment with highest
prevalence of use in the intensive care, general
medicine, and oncology units. Empiric antimicro-
bial therapy was most frequently used in the oncol-
ogy unit (Table 3). The two most common types of
infection requiring antimicrobial therapy were
respiratory tract and urinary tract infections; each
occurred more often in the acute care setting
(Table 4).
At the time of the survey, 10% of antimicrobial
orders (26/249; 1/21 in long-term care and 25/
228 in acute care) had been prescribed for greater
than 7 days and 6% (15/249; 1/21 in long term care
and 14/228 in acute care) had been prescribed for
greater than 14 days. Among the surgical prophy-
laxis orders, 25% (3/12) had been prescribed for
greater than 24 h and 8% (1/12) had been pre-
scribed for greater than 48 h. Of the prophylaxis
orders, eleven were for cefazolin, and one was
for ciprofloxacin, which was ordered by the urology
service.
The ID service was consulted in the previous
7 days for 26% (6/23) of patients who received
Fig. 1 Percentage of Antimicrobial use in Acute Care and Long-term Care*.
*Denominator is the total number of antimicrobial orders in acute care or long term care.
Note: aminoglycoside = tobramycin, gentamicin; carbapenem = ertapenem, meropenem; 1st cephalosporin = cefazo-
lin, cephalexin; 2nd cephalosporin = cefuroxime; 3rd cephalosporin = ceftazidime, ceftriaxone; fluoroquinolone =
ciprofloxacin, levofloxacin; glycopeptide = vancomycin; imidazole = metronidazole; lincosamide = clindamycin;
macrolide = erythromycin, azithromycin, clarithromycin; penicillin b-lactamase inhibitor = amoxicillin–clavulanic acid
or piperacillin–tazobactam; penicillin b-lactamase resistant = cloxicillin; penicillin b-lactamase sensitive = penicillin;
penicillin extended spectrum = amoxicillin or ampicillin; other antibiotic = rifampin, trimethoprim, dapsone, or
doxycycline; triazole = fluconazole, itraconazole, ketoconazole, voriconazole; other antifungal = caspofungin; nucle-
oside/nucleotide = acyclovir and valacyclovir.
Table 2 Prevalence of antimicrobial utilization.
Description Acute care Long-term care
Number of patients admitted 508 513
Number of patients receiving treatment (per 1000 patients) 156 21
(308) (41)
Number of all antimicrobial orders(per 1000 patients) 228 21
(449) (41)
Number of patients receiving one or more antimicrobial (%)
1 101 (65) 21 (100)
2 42 (27) 0
3 10 (6) 0
4 2 (1) 0
5 1 (0.6) 0
P6 0 0
146 C. Lee et al.empiric therapy and 35% (43/122) of patients who
received definitive antimicrobial therapy. How-
ever, ID was only consulted once for a resident inlong-term care. The ASP assessed therapy within
the previous 7 days for 4% (1/23) of patients who
received empiric therapy and 16% (20/122) of
Table 4 Number of patients treated based on indication/site of infection.
Indication Acute care
(n = 508)
Per 1000
inpatients
Long-term
care (n = 513)
Per 1000
inpatients
Definite
Respiratorya 43 85 11 22
Urinary tract (symptomatic) 24 48 1 2
Skin and soft tissue 17 32 4 6
Intra-abdominal 15 30 0 0
Bacteremiab 15 30 0 0
Clostridium difficile bacterial infection 10 20 0 0
Bone and joint 8 16 1 2
Central nervous system 4 8 0 0
Candida (mucosal) 3 6 0 0
Endocarditis 3 6 0 0
Urinary tract (asymptomatic) 3 6 3 6
Dental 2 4 0 0
Obstetrics/gynecology 1 2 0 0
Other definitivec 2 4 0 0
Empiric
Febrile neutropenia 8 16 0 0
SIRS/sepsis 7 14 0 0
Respiratory 3 6 0 0
Urinary tract 2 4 0 0
Intra-abdominal 1 2 0 0
Fever 1 2 0 0
Respiratory inflammation 1 2 0 0
Unknown
Unknown indication 6 12 1 2
Prophylaxis
Surgical 12 24 0 0
Medical 7 14 0 0
Note: Patients may be counted more than once if being treated for more than one indication (ie. one patient may be concurrently
treated for a urinary and respiratory tract infection) and therefore the sum of these indications does not represent the total
number of patients who have received an antimicrobial agent.
a Includes bacterial, viral (influenza), and fungal respiratory infections.
b Includes primary, secondary, and line related bacteremia.
c Given for prostate cancer and bullous pemphigoid.
Table 3 Prevalence of antimicrobial orders and patients receiving antimicrobial treatment per service.
Medical services Number of
patients receiving
an antimicrobial
(Per 1000 patients
to service)
Number of orders
(Per 1000 patients
to service)
Definite
orders
Empiric
orders
Unknown
orders
Prophylaxis
orders
Cardiology and cardiovascular
surgery* (n = 67)
17 (254) 25 (374) 18 3 0 4
Critical care* (n = 65) 29 (447) 47 (724) 37 4 1 7
Medicine* (n = 127) 47 (371) 62 (489) 55 6 0 2
Oncology* (n = 76) 29 (382) 49 (645) 34 15 3 1
Surgery/trauma* (n = 128) 31 (243) 42 (329) 29 2 3 8
Note: Orders may be counted more than once if being used for more than one indication (ie. one order may be used for a definite
and empiric indication) and therefore the sum of the definite, empiric, unknown, and prophylaxis orders does not represent the
total number of antimicrobials prescribed.
* Total number of patients admitted to the medical service at the time of the survey.
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therapy; all ASP assessments occurred in acute
care.
4. Discussion
Point prevalence surveys have been utilized exten-
sively to examine antimicrobial use in a number of
European countries [16–22]. To our knowledge,
this current study represents one of the first point
prevalence surveys designed to investigate antimi-
crobial use among hospitalized patients in a Cana-
dian adult tertiary care center. In the acute care
setting, nearly one third of hospitalized patients
were on at least one antimicrobial agent, and the
prevalence of antimicrobial orders was 449 per
1000 patients. These findings were similar to that
reported in a large multi-national European point
prevalence survey (2009 ESAC) where 29% of
patients received an antimicrobial agent and the
prevalence of antimicrobial orders was 407 per
1000 patients [18]. These findings were also consis-
tent with other smaller point prevalence surveys
conducted in a number of individual European
countries [16,17,20,21].
Similar to other point-prevalence surveys, b-lac-
tams were the most commonly used class of antibi-
otics in the acute care setting. However, when
comparing antibiotics within the b-lactam class,
our survey showed an overall lower use of penicil-
lins and higher use of cephalosporins compared to
other surveys [16–18,23,24]. This difference was
mostly driven by the greater use of first generation
cephalosporins and lesser use of penicillins with b-
lactamase inhibitors. Furthermore, the prevalence
of fluoroquinolone use in the acute care setting in
our survey (16%) was notably higher and almost
double than that reported in the 2009 ESAC survey
(9%) [18]. Interestingly, another Canadian point
prevalence survey, although primarily designed to
investigate the prevalence of hospital acquired
infections, showed a similar use of penicillins,
cephalosporins, and fluoroquinolones as in our
study [25]. In contrast to acute care, the preva-
lence of patients on antimicrobial therapy and
the prevalence of antimicrobial orders in the
long-term care setting were both lower. Although
b-lactams and fluoroquinolones were also most
commonly prescribed in the long-term care setting,
the proportion of residents treated with a third
generation cephalosporin or fluoroquinolone were
higher compared to patients in acute care. More
than 25% of residents on antibiotics in long-term
care were treated with a fluoroquinolone. Our
results were similar to those found in a Canadianpoint prevalence survey among long-term care
facilities in Ontario, with the exception that third
generation cephalosporin use was markedly higher
in our survey (14% vs. 1.2%) [26]. The reason for
this difference may be due to increased accessibil-
ity to intravenous medications at our hospital,
since it services both acute and long-term care
patients concurrently. A point prevalence survey
of European nursing homes also showed a similar
prevalence of overall antimicrobial use, again with
a higher use of penicillin antibiotics, particularly
amoxicillin–clavulanic acid (accounting for 40% of
all penicillin use) [19]. The reason for differences
in antimicrobial prescribing habits between coun-
tries is complex, and has been reported in a previ-
ous study comparing antimicrobial consumption
between North America and Europe [27]. Although
difficult to fully elucidate, differences may be due
to different opinions and traditions regarding infec-
tion treatment, differences in antimicrobial resis-
tance and guideline adherence, aggressive
marketing of newer agents, and differences in anti-
biotic-control programs [27,28]. Other clinicians
propose that the type of health care financing sys-
tems, number of doctors per inhabitant, and the
average time spent with patients may also lead to
different prescribing habits [29]. Also, unlike in
Europe, there are no ongoing regional initiatives
in North America to capture data on antimicrobial
use, which may have downstream impact on overall
antimicrobial consumption if such a surveillance
system was available. The results are also difficult
to compare since most point prevalence surveys do
not provide an assessment of the appropriateness
of therapy, which may also impact on the overall
prevalence of antimicrobial use.
Respiratory tract and urinary tract infections
were the most common indications for definitive
therapy in either acute or long-term care patients.
These were also the predominant indication for
fluoroquinolone use in our survey. Therefore, anti-
microbial stewardship initiatives targeting these
indications may have the greatest potential to
impact on patient care, antimicrobial use, inci-
dence of nosocomial infections (i.e. Clostridium
difficile), and resistance [13,30,31]. Another area
for antimicrobial stewardship intervention, as
suggested in previous surveys [16,18], is with anti-
microbial surgical prophylaxis. Among patients
receiving surgical prophylaxis, approximately one-
quarter of patients were receiving prophylaxis for
greater than 24 h at the time of this survey. The
majority of these cases would not have been eligi-
ble for ASP review in our facility because of the use
of a non-targeted antibiotic, and may present as an
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our institution.
Finally, there were fewer ID consults for long-
term care residents, likely due to lower severity
and complexity of infections in residents who
could continue to receive treatment for their
infections in the long-term care facility without
being transferred to acute care. The overall lower
frequency of ASP consults compared to ID
consults was expected because the ASP only con-
sulted on patients who received targeted antimi-
crobials on selected days of antimicrobial
therapy in acute care. At the time of this survey,
ASP services were not available to long-term care
residents. Given the prevalence of broad spec-
trum antibiotic use and the indications for antimi-
crobial use found in our survey, as of September
16, 2013, we instituted an ASP initiative in our
long-term care facility.
This study has important limitations inherent to
the use of point prevalence surveys. Point preva-
lence surveys look at a single point in time and so
the results can be affected by normal day-to-day
variation, existing trends, and seasonality of anti-
microbial use. Different antimicrobial agents can
be chosen for identical indications depending on
the prescribers judgment, which was not captured
in this study. Point prevalence surveys may also
over-represent antibiotic treatments that are given
for longer durations since they are more likely to
overlap the study date. Although highly trained
infectious diseases clinicians conducted the data
collection using a standardized form, there still
may be some differences in the interpretation of
data from incomplete charts, potentially leading
to discrepancies in assessments. Also, this survey
was conducted at a single university-affiliated
health center with policies and programs in place
to optimize antimicrobial prescribing. So, differ-
ences in patient population and prescribing prac-
tices should be considered when comparing these
results to other institutional point prevalence
surveys. But given the availability of national treat-
ment guidelines and similarities in prescribing
practices among academic teaching hospitals, the
results of this survey provides a good initial estima-
tion of institutional antimicrobial use in Canada.
Unfortunately, given the limited resources and
infrastructure, a Canadian multi-center point prev-
alence survey will not likely be initiated in the near
future. Finally, there is no international standard-
ized hospital categorization system, which makes
comparing hospitals from different countries
difficult.5. Conclusion
This study provides important insight into the use
of antimicrobial agents and prescribing patterns
at a Canadian tertiary care center. These results
will provide direction to future endeavors to
further optimize the use of antimicrobials at our
institution. Moreover, the results of this survey
brings to light the differences in antimicrobial use
between countries, and highlights the need for a
standardized nation-wide Canadian point-preva-
lence survey to better understand how antimicrobi-
als are being used in Canada and to establish the
first steps toward international antimicrobial
surveillance.
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